On December 15, 2025, NeOnc Technologies Holdings, Inc. announced updated clinical results from their ongoing study of intranasal NEO100 for treating recurrent IDH1-mutant astrocytoma patients.
AI Assistant
NEONC TECHNOLOGIES HOLDINGS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.